Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Harbin Pharmaceutical Group Co., Ltd. (600664.SS)
Harbin, CN
Harbin Pharmaceutical Group Co., Ltd. functions as a leading pharmaceutical company, overseeing the complete process from drug discovery and development to manufacturing and global sales. The firm's activities span both domestic Chinese markets and international territories. Its business structure is segmented into seven key areas: Antibiotics, Small-Molecule Drug Formulations, Over-the-Counter (OTC) and Health Products, Modern Chinese Medicine, Biopharmaceutical products, Animal Vaccines, and Pharmaceutical Distribution services. The company's broad product portfolio features a comprehensive selection of penicillin and cephalosporin antibiotics, in addition to vital pharmaceutical intermediates. Its notable offerings include various types of injections, such as Shuang Huanglian and Danshen freeze-dried injections, alongside a wide array of oral medications like roxithromycin dispersible tablets, amoxicillin capsules, and specialized pediatric granules containing paracetamol. The product line also encompasses a diverse range of antibiotics, highlighted by multiple cephalosporin-based injections (e.g., ceftriaxone sodium, cefepime hydrochloride) and penicillin derivatives, alongside extracts from traditional Chinese medicine like Panax ginseng. Furthermore, the group manufactures essential medical protective gear, including disposable surgical and protective masks, as well as isolation and protective gowns. These products are distributed under numerous well-known brands, including Hongyan Yaopin, Guangwei, Renmin Tongtai, and Hayao, among others. The company's headquarters are located in Harbin, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.06% | +0.90% | -5.87% | -4.53% | -6.39% | -2.32% | -12.01% | -7.42% | +13.85% | -57.88% | -21.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.3% Q1'26: +0.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-44.0% Q1'26: -20.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.1% Q1'26: -5.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.9% Q1'26: +5.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+7.2% ★ Q1'26: +10.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.7% Q1'26: -5.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.18× ★ Q1'26: 3.36× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.86B
est: 17.09B (-7.2%)
|
14.13B
est: 14.29B (-1.1%)
|
12.02B
est: 17.09B (-29.7%)
|
10.81B
est: 14.29B (-24.3%)
|
11.82B
est: 15.88B (-25.5%)
|
10.79B
est: 17.78B (-39.3%)
|
12.80B
est: 19.72B (-35.1%)
|
15.46B
est: 15.53B (-0.5%)
|
16.18B
est: 16.51B (-2.0%)
|
15.96B
est: 18.17B (-12.1%)
|
16.40B
16.40B – 16.40B
-9.7% YoY
|
16.94B
16.94B – 16.94B
+3.3% YoY
|
17.49B
17.49B – 17.49B
+3.3% YoY
|
| EBITDA |
1.21B
est: 676.91M (+79.5%)
|
1.41B
est: 565.78M (+148.8%)
|
984.50M
est: 676.91M (+45.4%)
|
882.28M
est: 565.78M (+55.9%)
|
550.35M
est: 628.87M (-12.5%)
|
-433.54M
est: 704.20M (-161.6%)
|
716.99M
est: 781.15M (-8.2%)
|
878.27M
est: 615.13M (+42.8%)
|
1.07B
est: 1.04B (+2.5%)
|
924.41M
est: 1.15B (-19.3%)
|
1.03B
1.03B – 1.03B
-9.7% YoY
|
1.07B
1.07B – 1.07B
+3.3% YoY
|
1.10B
1.10B – 1.10B
+3.3% YoY
|
| EBIT |
740.97M
est: 319.49M (+131.9%)
|
939.39M
est: 267.04M (+251.8%)
|
547.38M
est: 319.49M (+71.3%)
|
459.81M
est: 267.04M (+72.2%)
|
152.48M
est: 296.82M (-48.6%)
|
-803.30M
est: 332.37M (-341.7%)
|
447.79M
est: 368.69M (+21.5%)
|
618.44M
est: 290.33M (+113.0%)
|
849.71M
est: 795.10M (+6.9%)
|
615.29M
est: 875.22M (-29.7%)
|
790.07M
790.07M – 790.07M
-9.7% YoY
|
815.88M
815.88M – 815.88M
+3.3% YoY
|
842.47M
842.47M – 842.47M
+3.3% YoY
|
| Net Income |
580.13M
est: 503.08M (+15.3%)
|
788.10M
est: 716.89M (+9.9%)
|
406.98M
est: 503.08M (-19.1%)
|
346.14M
est: 716.89M (-51.7%)
|
55.81M
est: 1.11B (-95.0%)
|
-1.08B
est: 1.53B (-170.2%)
|
371.08M
est: 1.81B (-79.5%)
|
395.26M
est: 452.77M (-12.7%)
|
628.85M
est: 619.88M (+1.4%)
|
361.60M
est: 671.54M (-46.2%)
|
464.91M
464.91M – 464.91M
-30.8% YoY
|
542.40M
542.40M – 542.40M
+16.7% YoY
|
619.88M
619.88M – 619.88M
+14.3% YoY
|
| SGA |
2.94B
est: 3.53B (-16.7%)
|
2.56B
est: 2.95B (-13.1%)
|
2.30B
est: 3.53B (-34.9%)
|
2.19B
est: 2.95B (-25.8%)
|
2.35B
est: 3.28B (-28.4%)
|
2.78B
est: 3.67B (-24.3%)
|
2.29B
est: 4.07B (-43.8%)
|
3.13B
est: 3.21B (-2.4%)
|
3.38B
est: 2.96B (+14.0%)
|
1.96B
est: 3.26B (-40.0%)
|
2.95B
2.95B – 2.95B
-9.7% YoY
|
3.04B
3.04B – 3.04B
+3.3% YoY
|
3.14B
3.14B – 3.14B
+3.3% YoY
|
| EPS |
0.23
est: 0.20 (+15.0%)
|
0.32
est: 0.29 (+12.3%)
|
0.16
est: 0.20 (-20.0%)
|
0.14
est: 0.29 (-50.9%)
|
0.02
est: 0.44 (-95.5%)
|
-0.43
est: 0.61 (-170.5%)
|
0.15
est: 0.72 (-79.4%)
|
0.16
est: 0.18 (-11.1%)
|
0.25
est: 0.24 (+4.2%)
|
0.14
est: 0.26 (-46.2%)
|
0.18
0.18 – 0.18
-30.8% YoY
|
0.21
0.21 – 0.21
+16.7% YoY
|
0.24
0.24 – 0.24
+14.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 75.3K | 0.46% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 320.5K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 165.0K | 0.39% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 8.2K | 0.44% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 84.4K | 0.29% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 97.3K | 0.28% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 21.1K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.4K | 0.48% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.04M | 0.06% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.15M | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bangdong Li | Vice President | — | male |
| Chuanyou Lu | President & Director | — | male |
| Guangjun Diao | Vice President | — | male |
| Haitao Jiang | Vice President | — | male |
| Jicheng Xia | Vice President | — | male |
| Xiaodong Meng | Vice President, Secretary & Financial Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600664.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
